ArticleThe EMBO journal1995
A synthetic, chemically modified ribozyme eliminates amelogenin, the major translation product in developing mouse enamel in vivo.
Article in The EMBO journal, 1995. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
27 citing papers in PubMed, 138 citations in OpenAlex.
- Early evolution of enamel matrix proteins is reflected by pleiotropy of physiological functions.Scientific reports · 2023Article
- Proline-rich protein from S. mutans can perform a competitive mineralization function to enhance bacterial adhesion to teeth.Scientific reports · 2022Article
- Controls of nature: Secondary, tertiary, and quaternary structure of the enamel protein amelogenin in solution and on hydroxyapatite.Journal of structural biology · 2020Review
- Exon4 amelogenin transcripts in enamel biomineralization.Journal of dental research · 2015Article
- Alternative Splicing of the Amelogenin Gene in a Caudate Amphibian, Plethodon cinereus.PloS one · 2013Article
- Protein-mediated enamel mineralization.Frontiers in bioscience (Landmark edition) · 2012Review
- Identification of a novel splicing form of amelogenin gene in a reptile, Ctenosaura similis.PloS one · 2012Article
- The influence of Leucine-rich amelogenin peptide on MSC fate by inducing Wnt10b expression.Biomaterials · 2011Article
- The leucine rich amelogenin protein (LRAP) adsorbs as monomers or dimers onto surfaces.Journal of structural biology · 2010Article
- Article
- Enamel matrix proteins; old molecules for new applications.Orthodontics & craniofacial research · 2009Review
- A mouse model expressing a truncated form of ameloblastin exhibits dental and junctional epithelium defects.Matrix biology : journal of the International Society for Matrix Biology · 2009Article
- Structure, orientation, and dynamics of the C-terminal hexapeptide of LRAP determined using solid-state NMR.The journal of physical chemistry. B · 2008Article
- The structure and orientation of the C-terminus of LRAP.Biophysical journal · 2008Article
- pH triggered self-assembly of native and recombinant amelogenins under physiological pH and temperature in vitro.Journal of structural biology · 2007Article
- The nucleation and growth of calcium phosphate by amelogenin.Journal of crystal growth · 2007Article
- 3. Protein-protein interactions of the developing enamel matrix.Current topics in developmental biology · 2006Review
- Overexpression of TRAP in the enamel matrix does not alter the enamel structural hierarchy.Cells, tissues, organs · 2004Article
- Functional domains for amelogenin revealed by compound genetic defects.Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research · 2003Article
- Secondary structure prediction and in vitro accessibility of mRNA as tools in the selection of target sites for ribozymes.Nucleic acids research · 2000Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Ribozymes are small RNA structures capable of cleaving RNA target molecules in a catalytic fashion. Designed ribozymes can be targeted to specific mRNAs, blocking their expression without affecting normal functions of other genes. Because of their specific and catalytic mode of action ribozymes are ideal agents for therapeutic interventions against malfunctioning or foreign gene products. Here we report successful experiments to 'knock out' a major translation product in vivo using synthesized, chemically modified ribozymes. The ribozymes, designed to cleave amelogenin mRNA, were injected close to developing mandibular molar teeth in newborn mice, resulting in a prolonged and specific arrest of amelogenin synthesis not caused by general toxicity. No carriers were required to assist cellular uptake. Amelogenins are highly conserved tissue-specific proteins that play a central role in mammalian enamel biomineralization. Ultrastructural analyses of in vivo ribozyme-treated teeth demonstrated their failure to develop normally mineralized enamel. These results demonstrate that synthesized ribozymes can be highly effective in achieving both timed and localized 'knock-out' of important gene products in vivo, and suggest new possibilities for suppression of gene expression for research and therapeutic purposes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.